News
List of company announcements and press releases.
Click here for announcements regarding managers transactions.
Click here for news in Danish.
August 27, 2024 | Press Releases
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in SingaporeAugust 22, 2024 | Company Announcements
Bavarian Nordic Announces First Half 2024 ResultsAugust 21, 2024 | Company Announcements
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European CountryAugust 17, 2024 | Press Releases
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global StakeholdersAugust 16, 2024 | Press Releases
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to AdolescentsAugust 13, 2024 | Company Announcements
Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in AfricaAugust 13, 2024 | Company Announcements
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine August 08, 2024 | Company Announcements
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine ProductionJuly 26, 2024 | Press Releases
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox VaccineJuly 18, 2024 | Company Announcements
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine July 01, 2024 | Press Releases
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked LoanJune 28, 2024 | Press Releases
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa June 26, 2024 | Company Announcements
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMAJune 17, 2024 | Company Announcements
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate May 31, 2024 | Company Announcements
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox VaccineMay 30, 2024 | Press Releases
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in AfricaMay 22, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMay 21, 2024 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 21, 2024 | Company Announcements
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian NordicMay 08, 2024 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 08, 2024 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2024April 29, 2024 | Company Announcements
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic ReserveApril 29, 2024 | Company Announcements
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate April 16, 2024 | Company Announcements
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/SApril 02, 2024 | Press Releases
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.